Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — | MMWR https://www.cdc.gov/mmwr/volumes/72/wr/mm7221a3.htm “Among adults without immunocompromising conditions, #bivalent #booster #vaccine effectiveness (VE) against #COVID19–associated #hospitalization declined from 62% at 7–59 days #postvaccination to 24% at 120–179 days compared with VE among #unvaccinated adults.”